AstraZeneca (AZN) has entered a multi-year agreement to access Helix's genomic datasets to support research for drug discovery and development, Helix said Tuesday.

Under the agreement, AstraZeneca will gain access to Helix's GenoSphere cohorts, which combine Exome+ genomic sequencing and longitudinal clinical data across multiple disease areas, including cardiometabolic, respiratory and autoimmune disorders, among others, the company said.

Financial terms of the deal were not disclosed.

Shares of AstraZeneca were 1.3% higher in early Tuesday trading.

Price: 192.64, Change: +2.51, Percent Change: +1.32